WASHINGTON, March 26, 2015 /PRNewswire-USNewswire/ — On Tuesday, March 24, 2015, five advocacy groups representing a broad spectrum of physicians, pharmacists and patients – the American Autoimmune Related Diseases Association, Biologics Prescribers Collaborative, the Hematology/Oncology Pharmacy Association, National Alliance for Hispanic Health and National Organization for Rare Diseases – sent a letter to Office of Management and Budget Director Shaun Donovan underscoring the need for unique naming of biosimilars.
The groups called on Director Donovan to work with the U.S. Food and Drug Administration (FDA) to issue a unique naming policy for biosimilars, characterizing the final policy as “…urgent, given that the FDA has now approved the first biosimilar in the United States.”
The letter further states, “We commend the FDA for its careful deliberation on the naming issue and particularly for its carefully-crafted decision to give Zarxio (filgrastim-sndz) a temporary distinguishable name while the policymaking process continues.”
The letter, which was sent along with four letters previously sent by the respective organizations to FDA and one public statement in support of distinguishable naming, explains, “Given that no two biologics drugs can ever be the same, unique naming provides transparency that supports confidence in, and ultimately utilization of, these new medicines as well as critical post-market surveillance and tracking.”
Copies of the full letters and statement on distinguishable naming can be found on the Biologics Prescribers Collaborative website at https://biologicsprescribers.org/resources.
March 24, 2015
The Honorable Shaun Donovan
Director, Office of Management and Budget
The White House
725 17th Street, NW
Washington, DC 20503
Dear Director Donovan:
We are writing to urge the Office of Management and Budget to work with the U.S. Food and Drug Administration (FDA) to implement a policy of unique naming for all biosimilars and biologics. This is urgent, given that FDA has now approved the first biosimilar in the United States. The five groups submitting this letter – the American Autoimmune Related Diseases Association, Biologics Prescribers Collaborative, Hematology/Oncology Pharmacy Association, National Alliance for Hispanic Health, and National Organization for Rare Diseases – represent a broad spectrum of patients, providers, and pharmacists in favor of unique naming.
We commend the FDA for its careful deliberation on the naming issue and particularly for its carefully-crafted decision to give Zarxio (filgrastim-sndz) a temporary distinguishable name while the policymaking process continues.
We welcome the availability of biosimilars in the U.S. and believe the success of this class of medicines hinges on prescriber, patient, and pharmacist confidence. Every patient who depends on biologic drugs deserves to know the exact drug they are using in order to make the best medical decisions in terms of both efficacy and safety. Given that no two biologics drugs can ever be the same, unique naming provides transparency that supports confidence in, and ultimately utilization of, these new medicines as well as critical post-market surveillance and tracking.
Attached with this letter are four letters previously submitted to FDA from our respective organizations and one statement that details our case for unique naming. Thank you for your attention to this important patient safety matter. Given that biosimilars will be available in the U.S. imminently, we look forward to guidance on naming in the near future.
Respectfully,
American Autoimmune Related Diseases Association
Virginia T. Ladd, President and Executive Director
Biologics Prescribers Collaborative
Dennis R. Cryer, MD, Lead-Physician Co-convener
Hematology/Oncology Pharmacy Association
J. Michael Vozniak, PharmD, BCOP, President
National Alliance for Hispanic Health
Jane L. Delgado, Ph.D., M.S., President and CEO
National Organization for Rare Diseases
Peter L. Saltonstall, President and CEO
CC:
The Honorable Sylvia Burwell, Secretary, U.S. Department of Health and Human Services
The Honorable Margaret Hamburg, Commissioner, Food and Drug Administration
Mr. Howard Shelankski, Director, Office of Administration and Regulatory Affairs
Ms. Cecilia Muñoz, Director, Domestic Policy Council
Dr. Jonca Bull, Director, Office of Minority Health
Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research
Dr. Karen Midthun, Director, Center for Biologics Evaluation and Research
Dr. John Jenkins, Director, Office of New Drugs, Center for Drug Evaluation and Research
Dr. Anne Pariser, Associate Director for Rare Diseases, Center for Drug Evaluation and Research
Dr. Gayatri Rao, Director, Office of Orphan Products Development